Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRLHR | P49683 | 4/20 | 0.48 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.46 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.46 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.46 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CLPP | Q16740 | 2/20 | 0.40 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.40 |
| ▸ | PDE5A | O76074 | 1/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3297280 | 0.95 | PRLHR (0.51) | PRLHRTAS1R3TAS1R1TAS1R2MEN1 | |
| SCHEMBL3297975 | 0.95 | TAS1R3 (0.49) | PRLHRTAS1R3TAS1R1TAS1R2MEN1 | |
| SCHEMBL3300080 | 0.93 | TAS1R3 (0.45) | PRLHRTAS1R3TAS1R1TAS1R2MEN1 | |
| SCHEMBL3299046 | 0.92 | PRLHR (0.46) | PRLHRTAS1R3TAS1R1TAS1R2MEN1 | |
| SCHEMBL3300421 | 0.92 | PRLHR (0.50) | PRLHRTAS1R3TAS1R1TAS1R2MEN1 | |
| SCHEMBL3300133 | 0.91 | PRLHR (0.49) | PRLHRTAS1R3TAS1R1TAS1R2DGAT1 | |
| SCHEMBL3296502 | 0.91 | TAS1R3 (0.47) | PRLHRTAS1R3TAS1R1TAS1R2MEN1 | |
| SCHEMBL3299089 | 0.90 | PRLHR (0.46) | PRLHRTAS1R3TAS1R1TAS1R2MEN1 | |
| SCHEMBL3297705 | 0.89 | TAS1R3 (0.45) | PRLHRTAS1R3TAS1R1TAS1R2MEN1 | |
| SCHEMBL3298327 | 0.88 | MRGPRX4 (0.49) | PRLHRTAS1R3TAS1R1TAS1R2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8232282-B2 | Compound having bicyclic pyrimidine structure and pharmaceutical composition comprising the same | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-07-31 | — | — | US | disclosed |
| US-20100093771-A1 | Compound having bicyclic pyrimidine structure and pharmaceutical composition comprising the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-04-15 | — | — | US | disclosed |
| EP-2078719-A1 | COMPOUND HAVING BICYCLIC PYRIMIDINE STRUCTURE AND PHARMACEUTICAL COMPOSITION COMPRISING THE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2009-07-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093771-A1 | Compound having bicyclic pyrimidine structure and pharmaceutical composition comprising the same | GART, MGAT2, MGAT1 | PRLHR 3093/4885TAS1R3 2368/4885TAS1R1 1714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.